Last updated: March 13, 2026
What Is the Drug and Market Context?
NDC 51407-0554 identifies Tecentriq (atezolizumab), a PD-L1 immune checkpoint inhibitor manufactured by Genentech. Approved by the FDA since 2016, it treats various cancers, including non-small cell lung cancer (NSCLC), bladder cancer, triple-negative breast cancer, and small cell lung cancer (SCLC).
The drug's market has grown as immunotherapy becomes standard in oncology. Key competitors include Keytruda (pembrolizumab) and Opdivo (nivolumab). Tecentriq's revenues peaked at approximately $1.3 billion in 2021, reflecting its expanding indication base.
Market Size and Growth Trends
| Metric |
Data |
Notes |
| 2022 Global Oncology Immunotherapy Market |
$59 billion |
Expected CAGR (2022-2027): 10.5% (Fortune Business Insights) |
| U.S. Oncology Immunotherapy Revenue (2022) |
$25 billion |
Tecentriq holds ~8% market share in lung cancer |
| Key Indications for Tecentriq |
NSCLC, SCLC, bladder, breast |
Dominates in first-line NSCLC in combination therapy |
Market Drivers
- Increasing prevalence of lung and bladder cancers.
- Expanded FDA approvals for multiple indications.
- Growing use of combination regimens, e.g., Tecentriq with chemotherapy.
- Investment in biomarker-driven patient selection (PD-L1 testing).
Regulatory and Patent Landscape
- Patent expiration for Tecentriq is projected around 2033.
- Biosimilar development is progressing; no biosimilar approved as of 2023.
- Ongoing trials with broader indications may sustain or increase market share.
Price and Reimbursement Dynamics
| Pricing Factor |
2023 Price |
Notes |
| List Price (per 1200 mg dose) |
~$9,430 |
Based on wholesale acquisition cost (WAC) |
| Average Wholesale Price (AWP) |
~$12,500 |
Includes markup estimates |
| Medicare/Medicaid Reimbursement |
Negotiated |
Variability by state and provider |
Pricing in the U.S. remains high, driven by R&D costs, patent protections, and limited biosimilar entry. Price erosion is limited by value-based reimbursement models and ongoing demand.
Price Projections (2023–2028)
| Year |
Estimated Average Price (per 1200 mg dose) |
Changes & Assumptions |
| 2023 |
$9,430 |
Current list price |
| 2024 |
$9,200 |
Slight reduction due to negotiations and market pressure |
| 2025 |
$8,950 |
Potential cost containment measures |
| 2026 |
$8,700 |
Biosimilar threat may influence pricing stability |
| 2027 |
$8,450 |
Increased biosimilar activity and discounting |
| 2028 |
$8,200 |
Further biosimilar competition & price optimization |
This projection assumes moderate biosimilar entry starting around 2025 and ongoing market growth.
Competitive and Regulatory Risks
- Biosimilars could reduce prices by 20-30% over the next five years.
- New indications, especially in earlier lines, could sustain revenues.
- Regulatory delays or rejections may limit expansion.
- Price containment policies and value-based agreements might pressure margins.
Summary of Opportunities and Challenges
Opportunities
- Growing use in first-line NSCLC.
- Expanding approval for additional indications.
- Potential for combination therapies to extend patent exclusivity.
Challenges
- Price erosion from biosimilar competition.
- Patent litigation risks.
- Market saturation in key indications.
Key Takeaways
- Tecentriq remains a significant player in immuno-oncology, targeting a multi-billion-dollar market.
- Average U.S. pricing is around $9,400 per 1200 mg dose as of 2023.
- Price projections anticipate gradual declines driven primarily by biosimilar development starting mid-decade.
- Market growth hinges on indication expansion and competitive dynamics with Keytruda and Opdivo.
- Regulatory and patent landscapes will influence future revenue and pricing stability.
FAQs
-
When is Tecentriq's patent expected to expire?
Around 2033, with potential extensions for some formulations or indications.
-
Are biosimilars imminent for Tecentriq?
Biosimilar development is underway, but none are approved as of 2023. Entry could occur between 2025-2027.
-
What are Tecentriq's main competitors?
Keytruda (Merck) and Opdivo (Bristol-Myers Squibb) dominate the immuno-oncology segment.
-
How might new indications impact Tecentriq's market?
Approvals for additional cancers or earlier lines could sustain revenue growth despite patent challenges.
-
What factors most influence Tecentriq's pricing?
Market competition, biosimilar entry, reimbursement negotiations, and regulatory policies.
References
[1] Fortune Business Insights. (2022). Global Oncology Immunotherapy Market.
[2] U.S. Food and Drug Administration. (2022). FDA Approvals for Tecentriq.
[3] IQVIA. (2022). Market Dynamics in Oncology Drugs.
[4] Patents and Exclusivity Data. (2023). U.S. Patent Office.
[5] EvaluatePharma. (2023). Oncology Sales and Pricing Trends.
